

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/SA1A05B7212EN.html>

Date: November 2018

Pages: 84

Price: US\$ 3,500.00 (Single User License)

ID: SA1A05B7212EN

Abstracts

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H2 2018

SUMMARY

According to the recently published report 'SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2018'; Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Serine/threonine-protein kinase PLK1 is an enzyme encoded by the PLK1 (polo-like kinase 1) gene. It is highly expressed during mitosis and elevated levels are found in many different types of cancer. Depletion of this protein in cancer cells dramatically inhibited cell proliferation and induced apoptosis.

The report 'SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2018' outlays comprehensive information on the Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like

Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colorectal Cancer, Esophageal Cancer, Leukemias, Myelodysplastic Syndrome, Ovarian Cancer, Pancreatic Cancer, Skin Cancer, Anal Cancer, Breast Cancer, Cervical Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Human Papillomavirus (HPV) Associated Cancer, Juvenile Myelomonocytic Leukemia (JMML), Lung Cancer, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Penile Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sarcomas, Small-Cell Lung Cancer, Solid Tumor, Squamous Cell Carcinoma and Squamous Non-Small Cell Lung Cancer.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)

The report reviews Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which

includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics and enlists all their major and minor projects

The report assesses Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's

most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Overview

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Companies Involved in Therapeutics

Development

Adhera Therapeutics

Boehringer Ingelheim GmbH

Cyclacel Pharmaceuticals Inc

Onconova Therapeutics Inc

PhoreMost Ltd

Takeda Pharmaceutical Co Ltd

Trovagene Inc

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Drug Profiles

Antisense Oligonucleotide to Target MIR34 and PLK1 for Pancreatic Ductal

Adenocarcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CYC-140 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LS-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onvansertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PM-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rigosertib sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PLK1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PLK1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

volasertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Dormant Products

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Discontinued Products

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Product Development Milestones

Featured News & Press Releases

Nov 05, 2018: Onconova announces four presentations from Rigosertib clinical trials in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting & Exposition

Oct 24, 2018: New patent claims strengthen patent estate revenue aligns with Onvansertib clinical development and biomarker strategy in AML

Oct 18, 2018: Trovogene to provide update on Onvansertib clinical development program on October 24, 2018

Oct 17, 2018: Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib

Sep 27, 2018: Trovogene Announces Completion of Dosing Cohort of Patients Treated with Onvansertib in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial

Sep 05, 2018: Trovogene announces predictive clinical biomarker approach to identify Acute Myeloid Leukemia patients most likely to respond to Onvansertib

Aug 29, 2018: Trovogene announces European Commission grants orphan drug designation to Onvansertib (PCM-075) for treatment of acute myeloid leukemia in Europe

Aug 21, 2018: Onconova Therapeutics announces plan for expanding Rigosertib clinical trials for patients with Myelodysplastic Syndromes to South America with Pint Pharma

Aug 16, 2018: Trovogene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial

Aug 15, 2018: Trovogene Receives USAN Approval for Onvansertib as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075

Aug 01, 2018: Trovogene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Investigational Cancer Drug

Jun 27, 2018: Trovogene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML

Jun 21, 2018: Trovogene starts enrolment in Phase II trial of PCM-075 and Zytiga

Jun 15, 2018: Trovogene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial

Jun 07, 2018: Onconova Therapeutics Announces Presentation at the 23rd Congress of the European Hematology Association

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Adhera Therapeutics, H2 2018
Pipeline by Boehringer Ingelheim GmbH, H2 2018
Pipeline by Cyclacel Pharmaceuticals Inc, H2 2018
Pipeline by Onconova Therapeutics Inc, H2 2018
Pipeline by PhoreMost Ltd, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Trovogene Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Adhera Therapeutics

Boehringer Ingelheim GmbH

Cyclacel Pharmaceuticals Inc

Onconova Therapeutics Inc

PhoreMost Ltd

Takeda Pharmaceutical Co Ltd

Trovagene Inc

I would like to order

Product name: Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/SA1A05B7212EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SA1A05B7212EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

